Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakoda, Teppei, Kanamitsu, Yoko, Mori, Yasuo, Sasaki, Kensuke, Yonemitsu, Etsuko, Nagae, Konosuke, Yoshimoto, Goichi, Kamezaki, Kenjiro, Kato, Koji, Takenaka, Katsuto, Miyamoto, Toshihiro, Furue, Masutaka, Iwasaki, Hiromi, Akashi, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643178/
https://www.ncbi.nlm.nih.gov/pubmed/28824063
http://dx.doi.org/10.2169/internalmedicine.8491-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643178/
https://www.ncbi.nlm.nih.gov/pubmed/28824063
http://dx.doi.org/10.2169/internalmedicine.8491-16

Ejemplares similares